Zacks Investment Research downgraded shares of aTyr Pharma, Inc. (NASDAQ:LIFE) from a buy rating to a hold rating in a research report report published on Wednesday, October 18th.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other analysts have also recently issued reports about the company. ValuEngine upgraded aTyr Pharma from a sell rating to a hold rating in a report on Saturday, July 8th. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the company a hold rating in a research note on Tuesday, August 15th. Finally, Piper Jaffray Companies assumed coverage on aTyr Pharma in a research note on Thursday, September 7th. They issued an overweight rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $4.62.
aTyr Pharma (LIFE) traded up $0.05 on Wednesday, hitting $4.50. The stock had a trading volume of 32,443 shares, compared to its average volume of 113,753. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $6.50. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.13 and a quick ratio of 6.13.
aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. sell-side analysts predict that aTyr Pharma will post -2.09 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “aTyr Pharma, Inc. (NASDAQ:LIFE) Downgraded by Zacks Investment Research to “Hold”” was published by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://baseballnewssource.com/markets/zacks-investment-research-lowers-atyr-pharma-inc-life-to-hold/1722856.html.
In other news, CEO John Mendlein bought 37,736 shares of the stock in a transaction dated Thursday, August 31st. The stock was bought at an average price of $2.65 per share, for a total transaction of $100,000.40. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Paul Schimmel bought 94,336 shares of the stock in a transaction dated Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $249,990.40. Following the purchase, the director now owns 40,440 shares in the company, valued at $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.
An institutional investor recently bought a new position in aTyr Pharma stock. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 90,020 shares of the biotechnology company’s stock, valued at approximately $455,000. Victory Capital Management Inc. owned 0.38% of aTyr Pharma as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 47.01% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with our FREE daily email newsletter.